To hear about similar clinical trials, please enter your email below

Trial Title: Multicenter Study to Evaluate a Systematized Communication Model for Breast Cancer Patients

NCT ID: NCT05837533

Condition: Breast Cancer Stage IV
Breast Cancer Metastatic
Communication

Conditions: Official terms:
Breast Neoplasms

Study type: Interventional

Study phase: N/A

Overall status: Recruiting

Study design:

Allocation: Non-Randomized

Intervention model: Sequential Assignment

Intervention model description: During the first half of the study, patients will be assigned to the control group where they will receive information through their usual care from their oncologist during their medical consultation. In the second half of the study, patients will be assigned to the intervention group where they will receive information through the communication model used by their oncologist during their medical consultation. In this way, the contamination of the control group with attention corresponding to the systematized communication model under study will be avoided.

Primary purpose: Other

Masking: Double (Participant, Outcomes Assessor)

Masking description: Participants will not be informed whether they will be allocated to the control or intervention group.

Intervention:

Intervention type: Other
Intervention name: Communication model
Description: During the medical consultation of each patient assigned to the intervention group, the oncologist will use the systematic communication model for patients with metastatic breast cancer. For this, the oncologist will follow the conversation guide for patients with metastatic breast cancer, which will allow directing the conversation towards information about the patient's diagnosis, treatment and prognosis. The guide consists of a series of steps and questions to be asked to the patient in order to explore her understanding of her disease and her information preferences, as well as to facilitate the oncologist providing said information to the patient. The responses to each item in the guide will be electronically documented by the oncologist.
Arm group label: Intervention group

Summary: Both in Mexico and in the world, breast cancer is the most common malignancy in women. It is estimated that in 2020, 28.2% of the new cancer cases reported in our country correspond to breast cancer, which translates to 30,000 new cases. In addition, it is relevant to mention that approximately 12% of Mexican patients are diagnosed with stage IV breast cancer and it is estimated that 20-30% of women with early stage cancer will have a distant recurrence of the disease. Thus, about 40% of patients will find themselves in a metastatic stage at some point in their breast cancer journey. Various studies, including Mexico, report that only half of patients with metastatic breast cancer are aware that their disease is not curable, 31% say they are not sure, and 17% think it is curable. Likewise, 58% considered that they did not have enough knowledge to actively participate in conversations about their therapeutic options, which means that 40% reported difficulty talking about treatments with their doctors. This has shown that there are suboptimal levels of knowledge information on curability, treatment objectives and prognosis of their condition in patients with metastatic breast cancer. This lack of understanding is alarming given that a general understanding of the disease is crucial for informed decision making and adherence to cancer treatment. Due to these alarming results, we seek to recruit women ≥18 years of age who are candidates to start first- or second-line treatment for de novo or recurrent metastatic breast cancer from various hospital centers in the country with public and private coverage, including Hospital Zambrano Hellion TecSalud as coordinating center in Nuevo León. The objective will be to evaluate whether a systematized communication model for patients with metastatic breast cancer allows increasing knowledge about the non-curative nature of treatment, compared to usual care.

Criteria for eligibility:
Criteria:
Inclusion Criteria: - Diagnosis of de novo or recurrent metastatic breast cancer - Candidate to start the first or second line of treatment for metastatic breast cancer Exclusion Criteria: - Receipt of a line of treatment for metastatic breast cancer posterior to the second line

Gender: Female

Minimum age: 18 Years

Maximum age: N/A

Healthy volunteers: No

Locations:

Facility:
Name: Hospital Zambrano Hellion

Address:
City: San Pedro Garza Garcia
Zip: 66278
Country: Mexico

Status: Recruiting

Contact:
Last name: Cynthia Villarreal-Garza, MD, DSc

Start date: May 17, 2023

Completion date: June 2025

Lead sponsor:
Agency: Medicos e Investigadores en la Lucha contra el Cancer de Mama
Agency class: Other

Source: Medicos e Investigadores en la Lucha contra el Cancer de Mama

Record processing date: ClinicalTrials.gov processed this data on November 12, 2024

Source: ClinicalTrials.gov page: https://clinicaltrials.gov/ct2/show/NCT05837533

Login to your account

Did you forget your password?